Current clinical trials

Current clinical trials

Study (Acronym) & Study TypeSponsor/ClientStudy Director/SDPStaff (IBE)Status
APART:
Efficacy of the Affolter Model® in Patients with Ataxia Following a Stroke: A Randomized, Controlled, Blinded Clinical Trial with a Parallel-Group Design and Repeated Measurements
University of AugsburgProf. Dr. E. Grill
Prof. Dr. A. Bender
Dr. R. StroblProtocol Development
CML Absetzregister:
Scientific Registry for the Prospective Documentation of Treatment-Free Remission in Chronic Myeloid Leukemia, with the Goal of Investigating Prognostic Factors
University of HeidelbergProf. Dr. S. SaußeleProf. Dr. M. Pfirrmann
A. Albeer
Recruitment
ESTIMATION: Efficacy of asciminib in chronic phase CML patients with T315I mutationsFriedrich-Schiller-University of JenaProf. Dr. T. ErnstProf. Dr. M. Pfirrmann
T. Brenninger-Lang
Protocol Development
PROTAGORAS: PROTamine Application in patients underGOing tRAnScatheter aortic valve replacement (PROTAGORAS)LMU HospitalProf. Dr. S. Massberg
Prof. Dr. L. Weckbach
PD Dr. M. Lauseker-Hao
Dr. Y. Xu
Recruitment
ARTIST: Risk-adapted frontline treatment with AsciminibFriedrich-Schiller-University of JenaProf. Dr. T. ErnstProf. Dr. M. Pfirrmann
A. Albeer
Protocol Development
ECWM-2: Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s MacroglobulinemiaUlm University HospitalProf. Dr. C. BuskeProf. Dr. E. Hoster
K. Gutmair
Evaluation
PLATO: Glofitamab Combined With Pirtobrutinib in Relapsed/Refractory Patients with Mantle Cell Lymphoma Followed by an Extension in Treatment Naïve Patients: a phase II trial of the European MCL NetworkLMU HospitalDr. C. SchmidtProf. Dr. E. Hoster
L. Jiang
Recruitment
EEN-RICH: A randomized, double-blind, placebo-controlled, phase I/II trial of multi-donor fecal microbiota transfer for maintenance of Remission after Induction treatment with Exclusive Enteral Nutrition (EEN) in CroHn’s disease (EEN-RICH study)LMU Hospital - Dr. von Haunersches KinderspitalPD Dr. T. SchwerdProf. Dr. E. Hoster
L. Jiang
Recruitment
VIWA-1: Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia (VIWA-1) – a multicenter, randomized, explorative open label phase II international studyUlm University HospitalProf. Dr. C. BuskeProf. Dr. E. HosterRecruitment
COUP-1: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients – a multicenter open label single-arm phase II studyUlm University HospitalProf. Dr. C. BuskeProf. Dr. E. HosterRecruitment
PRiSMA: Pediatric Stroke Registry as a Multidisciplinary Platform for Targeted Research and CareLMU Hospital - Dr. von Haunersches KinderspitalPD Dr. L. GerstlPD Dr. M. Lauseker-Hao
J. Fusiak
Recruitment
PRIDE: PRotective VEGF Inhibition for Isotoxic Dose Escalation in GlioblastomaLMU HospitalProf. Dr. M. NiyaziProf. Dr. U. MansmannRecruitment
CARMAN: Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B): a randomized phase II studyLMU Hospital - Med IIIProf. Dr. M. DreylingProf. Dr. E. Hoster
L. Jiang
Recruitment
MASPAC: MR-Guided Adaptive Stereotactic Body Radiotherapy (SBRT) of Primary Tumor for Pain Control in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) – a Randomized, Controlled Clinical StudyLMU HospitalProf. Dr. M. NiyaziProf. Dr. U. Mansmann
M. Müller
Dr. Y. Xu
Evaluation
EPIDAURUS: Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary syndrome undergoing percutaneoUS coronary interventionLMU HospitalPD Dr. K. RizasProf. Dr. U. MansmannRecruitment
PROFIL: Effect of propionate supplementation as an anti-inflammation approach on neurofilaments in patients with corticobasal syndrome (CBS): Double-blind, randomized, placebo-controlled, parallel-group, phase II studyLMU Hospital - DSGZProf. Dr. J. LevinProf. Dr. U. MansmannRecruitment
MCL Elderly III: Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapyMainz University HospitalProf. Dr. G. HessProf. Dr. E. Hoster
L. Jiang
Recruitment
ALTERNATIVE-C: A prospective multicenter phase 2 study of the chemotherapy-free combination of the intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor Copanlisib in combination with Obinutuzumab in patients with previously untreated follicular lymphoma (FL) and a high tumor burdenLMU Hospital - Med IIIDr. C. SchmidtProf. Dr. E. Hoster
Dr. V. Jurinovic
Evaluation
CZAR-1: Randomized Phase 3 Trial by the European Consortium for Waldenström's Macroglobulinemia on the Treatment of Waldenström's Macroglobulinemia with Ibrutinib, With or Without CarfilzomibUlm University HospitalProf. Dr. C. BuskeProf. Dr. E. HosterRecruitment
XVIR-01: Single center, open-label, phase I, dose finding and safety study on the oncolytic adenovirus XVir-N-31 in patients with recurrent glioblastoma (XVIR-01)Goethe-University of
Frankfurt
Prof. Dr. J. P. SteinbachPD Dr. M. Lauseker-HaoProtocol Development
PyloResPres: Pylorus resection versus pylorus preservation in pancreatoduodenectomy: A multicenter surgical registry-based randomized active-controlled trial (RRCT) from the German DGAV StuDoQ|Pancreas RegistryLMU HospitalProf. Dr. J. WernerDr. A. CrispinEvaluation
PONTrack: Prospective, non-randomised, open-label, multicentre phase II trial of patients with CML treated with Ponatinib in order to assess MR4 achievement after 2 years of treatmentUniversity of HeidelbergProf. Dr. S. SaußeleProf. Dr. M. Pfirrmann
A. Albeer
Evaluation
FASCINATION: Prospective, non-randomised, open-label, multicentre phase II trial of patients with de novo BCR-ABL1 positive CML in chronic phase, treated with a combination of an established TKI and asciminib in order to assess impact on deep molecular responseFriedrich-Schiller-University of JenaProf. Dr. T. ErnstProf. Dr. M. Pfirrmann
T. Brenninger-Lang
Recruitment
BlastCrisis: European CML blast crisis registry for patients with CML in blast crisisFriedrich-Schiller-University of JenaDr. C. Fabisch
PD Dr. A. Brioli
PD Dr. M. Lauseker-Hao
PD Dr. M. Lauseker-HaoEvaluation
TRACE: Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific CD4+ and CD8+ T cells against AdV, CMV and EBV: A Phase III, prospective multicentre clinical trial. Multivirus-specific T-cell transfer post SCT vs AdV, CMV and EBV infectionsAlbert-Ludwigs-University of FreiburgProf. Dr. T. FeuchtingerProf. Dr. M. PfirrmannRecruitment
MARTHA: Milk Against Respiratory Tract Infections and AsthmaLMU Hospital - Dr. von Haunersches KinderspitalProf. Dr. E. von MutiusProf. Dr. U. MansmannRecruitment
GABe2016: First line therapy of advanced stage follicular lymphoma in patients < 60 years not eligible for standard immunochemotherapy and all patients ≥ 60 years - Prospective randomized evaluation of single agent GA101 versus GA101 plus Bendamustine followed by GA101LMU HospitalProf. Dr. C. BuskeProf. Dr. E. Hoster
Dr. V. Jurinovic
Evaluation
RESIST: Optimization of individualized therapy for CRCs with secondary RESISTance towards anti-EGFR targeted therapy using an avatar model (Colon-Resist-Net)LMU HospitalProf. Dr. S. StintzingProf. Dr. U. MansmannRecruitment
NAUT: Multicenter Prospective Trial after first unsuccesful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of Nilotinib in inducing the persistence of molecular remission after stopping TKI a 2nd timeUniversity of HeidelbergProf. Dr. S. SaußeleProf. Dr. M. Pfirrmann
A. Albeer
Recruitment
HyperTET: Trabectedin with Regional Hyperthermia as second line treatment for patients with advanced soft-tissue sarcomaLMU Hospital - Med III/ HyperthermieProf. Dr. R. IsselsProf. Dr. U. Mansmann
Dr. Y. Xu
Evaluation
TRIANGLE: Autologous transplantation after a Rituximab/Ibrutinib/Ara-C containing induction in generalized mantle cell lymphoma –a randomized European mcl network trialLMU Hospital - Med IIIProf. Dr. M. DreylingProf. Dr. E. Hoster
L. Jiang
Evaluation